Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Ongoing Phase 1/2 Trial Advancing to Phase 2 Evaluation of Multi-Antigen Vaccine, Targeting both Spike and Nucleocapsid Proteins, as a Universal Booster to Current FDA-Approved Vaccines ATLANTA, GA,...
-
The GeoVax Multi-antigenic MVA-VLP Approach Designed to Provide a Stronger, Broader Protection Atlanta, GA, Dec. 14, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq:...
-
Nonhuman Primate Testing of Sudan and Marburg Vaccine Candidates Demonstrates Efficacious Immune Response ATLANTA, GA, Dec. 03, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc....
-
GEO-CM02 Being Developed as a Universal Vaccine to Address Evolving SARS-CoV-2 Variants such as Omicron ATLANTA, GA, Dec. 01, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc....
-
GEO-CM02 Being Developed as a Universal Vaccine to Address Evolving SARS-CoV-2 Variants ATLANTA, GA, Nov. 17, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a...
-
GeoVax Intellectual Property Portfolio Includes More than 70 Granted/Pending Patent Applications Atlanta, GA, Nov. 16, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq:...
-
ATLANTA, GA, Nov. 15, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies,...
-
Progress in Clinical Development of COVID-19 and Immuno-Oncology ProgramsATLANTA, GA, Nov. 11, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology...
-
Phase 2 Vaccine Designed to Enhance Response for Immunocompromised Patients Complements GeoVax’s Pan-Coronavirus Vaccine Program ATLANTA, GA and DUARTE, CA, Nov. 09, 2021 (GLOBE NEWSWIRE)...
-
Conference call to be held Thursday, November 11, at 4:30 p.m. Eastern Time ATLANTA, GA, Nov. 04, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX) (“GeoVax” or the...